Document Detail


Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency.
MedLine Citation:
PMID:  20672448     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: To determine patient and treatment characteristics associated with vitamin D deficiency (VDD) in an UK inner city HIV-1-positive adult cohort.
METHODS: Two hundred twenty-seven HIV-positive patients attending prospectively for routine blood tests in winter had serum 25-hydroxyvitamin D and parathyroid hormone (PTH) concentrations and other routine chemistry measured. Those with and without VDD were defined as having serum 25-hydroxyvitamin D concentrations <50 nmol/L and >75 nmol/L, respectively. Characteristics were compared between patients with and without VDD. The effects of VDD, tenofovir use, and their interaction on chemical measures were investigated.
RESULTS: VDD was found in 57% (131 of 227) of patients. Independent associations included nonwhite ethnicity [adjusted odds ratio (95% confidence interval): 7.40 (2.52 to 21.7)], higher random blood glucose [2.38 (1.24 to 4.57) per mmol/L], higher estimated glomerular filtration rate [eGFR: 1.04 (1.01 to 1.06)], and higher PTH [1.19 (1.00 to 1.42)]. PTH was higher in those receiving tenofovir (median 7.2 pmol/L) than other patients (4.3; P < 0.001) overall, but high PTH with tenofovir occurred only in the context of VDD. Tenofovir use was not associated with serum creatinine or eGFR overall but interacted with vitamin D status (P = 0.05 and P = 0.08, respectively), being linked to somewhat higher creatinine and lower eGFR among patients without VDD but higher eGFR in VDD patients.
CONCLUSIONS: 25(OH) VDD is associated with tenofovir-linked hyperparathyroidism and also with higher eGFR.
Authors:
Melanie M Rosenvinge; Keertie Gedela; Andrew J Copas; Anne Wilkinson; Catriona A Sheehy; Gul Bano; Phillip E Hay; Mark R Pakianathan; S Tariq Sadiq
Related Documents :
2494598 - Parathyroid sonography in secondary hyperparathyroidism: correlation with clinical find...
15075998 - Prevalence and clinical associations of prolonged prothrombin time in adult untreated c...
12729778 - Hypercalcemic complication in patients with oral squamous cell carcinoma.
14668738 - Negative preoperative localization studies are highly predictive of multiglandular dise...
2343728 - Qt interval of the ecg, heart rate and arterial pressure using propofol, methohexital o...
2688768 - Diagnosis and management of headache.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  54     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-29     Completed Date:  2010-08-12     Revised Date:  2011-09-06    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  496-9     Citation Subset:  IM; X    
Affiliation:
Department of Genitourinary Medicine, St. George's Healthcare NHS Trust, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenine / adverse effects,  analogs & derivatives*,  therapeutic use
Adult
Female
Great Britain
HIV Infections / complications*,  drug therapy*,  virology
HIV-1 / isolation & purification
Humans
Hyperparathyroidism / chemically induced*
Male
Middle Aged
Parathyroid Hormone / blood
Phosphonic Acids / adverse effects*,  therapeutic use*
Urban Population
Vitamin D / analogs & derivatives,  blood
Vitamin D Deficiency / complications*
Chemical
Reg. No./Substance:
0/Parathyroid Hormone; 0/Phosphonic Acids; 107021-12-5/tenofovir; 1406-16-2/Vitamin D; 64719-49-9/25-hydroxyvitamin D; 73-24-5/Adenine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experie...
Next Document:  The first and the last will become the best